MRK

Merck & Co
D

MRK

Arincen67/100B

Merck & Co P/E ratio

Merck & Co's P/E ratio is 149.70: its share price of 146.71 over its earnings per share of 0.98 over the last twelve months.

Today
149.70
Forward P/E, next 12 months
18.25
PEG ratio
24.28
Median, 5 years
20.21
Low, 5 years
10.67
High, 5 years
879.40

P/E ratio = price ÷ EPS (last 12 months) = 146.71 ÷ 0.98 = 149.70

Each day's closing price over the earnings per share of the last four quarters reported by that day (basic EPS, adjusted for splits). The P/E moves with the price every day and with the earnings at each report.

The forward P/E divides the price by the analysts' average EPS estimate for the next twelve months: the fiscal year in progress for the months left in it, the next one for the rest. For past days it uses each year's latest estimate, as the estimates of the time were not recorded (we keep a daily copy from November 2026), so the past line reads the price against the earnings expected by the time each year was reported.

Is Merck & Co's P/E high compared with its own history?

Merck & Co's P/E of 149.7 is near the top of its 5-year range (10.7 to 879.4, median 20.2). Analysts do not expect faster growth than in recent years, so it is expensive compared with its own history.

Is the price fair? See the whole check

A P/E is compared with the stock's own last five years, not with other companies. Why the market pays more or less (news, rates, the sector) is not in these figures.

P/E ratio by year and by quarter

Fiscal yearPeriod endingP/E ratioForward P/EMarket capNet income
FY2027 · Estimate31 Dec 202716.46———
FY2026 · Estimate31 Dec 202653.00———
Today149.7018.25361.96B2.45B
FY202531 Dec 202514.4338.03263.36B18.25B
FY202431 Dec 202414.7011.13251.88B17.13B
FY202331 Dec 2023760.7514.55277.67B365.00M
FY202231 Dec 202219.3479.62280.93B14.53B
FY202131 Dec 202115.6910.36193.90B12.36B
FY202031 Dec 202027.8714.11197.34B7.08B
FY201931 Dec 201922.7515.89222.44B9.78B
FY201831 Dec 201830.5015.51188.89B6.19B
FY201731 Dec 201759.8313.64144.67B2.42B
FY201631 Dec 201639.1515.66154.29B3.94B
FY201531 Dec 201531.4214.64140.09B4.46B
FY201431 Dec 201412.8816.66153.69B11.93B
FY201331 Dec 201330.9315.73139.70B4.52B
FY201231 Dec 201218.7612.43118.16B6.30B
FY201131 Dec 201117.1011.45109.32B6.39B
FY201031 Dec 2010108.3210.23106.38B982.00M
FY200931 Dec 20095.6412.0173.46B13.02B
FY200831 Dec 20087.939.9961.92B7.81B
FY200731 Dec 200736.7219.23120.27B3.28B
FY200631 Dec 200620.4215.7590.52B4.43B
FY200531 Dec 200514.3914.3266.64B4.63B
FY200431 Dec 200411.7013.5568.01B5.81B
FY200331 Dec 200314.4216.3798.53B6.83B
FY200231 Dec 200217.0418.25121.86B7.15B
FY200131 Dec 200117.6218.71128.30B7.28B
FY200031 Dec 200030.1930.20205.94B6.82B
FY199931 Dec 199925.5524.96150.48B5.89B
FY199831 Dec 199831.9030.28167.42B5.25B
FY199731 Dec 199726.3224.75121.46B4.61B
FY199631 Dec 199623.7320.9492.08B3.88B
FY199531 Dec 199523.19—77.36B3.34B
FY199431 Dec 199415.25—45.71B3.00B
FY199331 Dec 199317.45—37.79B2.17B
FY199231 Dec 199215.82—38.71B2.45B
FY199131 Dec 199128.76—61.02B2.12B
FY199031 Dec 199018.78—33.44B1.78B
FY198931 Dec 198919.56—29.24B1.50B
FY198831 Dec 198818.00—21.72B1.21B
FY198731 Dec 198722.70—20.58B906.40M
FY198631 Dec 198624.30—16.42B675.70M
FY198531 Dec 198517.29—9.33B539.90M

Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters. A forecast year's P/E is today's price over the analysts' EPS estimate for that year.

See also:Market cap,P/S ratio,Dividend yield,ROE (return on equity),Debt to equity,Current ratio,All ratios

Common questions about Merck & Co's P/E ratio

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.